李元念：我们正拥有生物医药创新和发展的黄金时代 | 研发客年会主席致辞
每年到了新药临床高峰论坛召开之际，研发客的团队都会既兴奋又紧张的期待这一盛会的到来。如往届大会一般，研发客特邀一位业内资深老师作为大会主席，和我们一道欢迎远道而来的朋友。
今年我们邀请了杭州泰格首席医学官李元念博士担任大会主席。李博士曾任江苏豪森药业临床研发高级副总裁，武田制药上海开发中心总经理。他有丰富的全球药物开发实战经验，对法规也有深刻的理解和洞察。您可以与他近距离交流，一睹他主持大会的风采。以下是李博士特别为大会撰写的欢迎词，我们4月24日上海见！
Dear distinguished guests,
It gives me a great pleasure to welcome all of you and chair the opening of the 3rd Clinical Development Summit organized by Drug RNDer and sponsored by Hangzhou TigerMed.
On behalf of Drug RNDer, we are proud to host the 3rd Clinical Development Summit today at this wonderful place with all of you. With successful track records over the past 3 years, our Clinical Development Summit has been positioned to provide not only first-hand information about novel drug development strategy, establish effective communication networks in the pharmaceutical industry, but also to partner with pharmaceutical companies in China for supporting their novel drug development effort.
报名请点击图片
The pharmaceutical market in China has evolved significantly over the past five years. The revolutionary development in the regulatory review process has expediated approval timelines dramatically and joining the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) helps ensure that pharmaceutical companies in China follow the same global standards as other markets. Continued Government effort in biopharmaceutical innovation and influx of capital in recent years to the pharmaceutical industry in China have presented a golden opportunity for today’s biotech companies.
China will take on a more integral role in global drug research and development, allowing countries to access this high growth market as part of a fully integrated global development plan. This will enable pharmaceutical companies in China to develop more robust, harmonized and de-risked global drug development programs.
All of these promising developments has closed the gap between China and other countries in drug research and development, which is a win for both the industry and more importantly the patients.
I sincerely wish that the 3rd Clinical Development Summit will again prove to be a venue for future-oriented symposium with the single goal of bringing new medicines and treatment solutions to our patients in China and around the world.
Welcome and have a successful 3rd clinical development submit!
Benny Li, PhD
Chief Medical Officer
Hangzhou TigerMed
各位尊敬的来宾们：
非常荣幸的欢迎大家参加本次由《研发客》主办、杭州泰格医药协办的第三届中国新药临床开发高峰论坛。
感谢《研发客》，让业界同仁有机会在此齐聚一堂。回顾过往三年，中国新药临床开发高峰论坛已不仅仅是新药研发策略的前沿信息分享和制药企业的高效沟通平台，而是已发展成为中国药企开展新药研发事业的切切实实的协助者。
过去5年来，中国药药物行业也发生了深刻变化。法规的变革，使得药物审批时间得以显著缩减；加入ICH（人用药品注册技术要求国际协调会），帮助中国药企得以与国际标准同步。政府不断为生物医药创新提供助力，以及近年来资本向行业内的不断涌入，都无不显示出，现今的生物制药技术企业正拥有一个黄金时代。
中国药企将更加深入的参与国际药物研发，同时，也让外企有机会参与分享中国高速发展的医药市场。这样的生态环境将促使中国的制药公司建立起自己更为坚实和丰富的研发管线，以及更加科学和有效的全球研发计划。
所有这些行业的进步，将使得中国与其他国家在药物研发上存在的差异快速消除。中国将于世界同步，这不只对行业，更重要的是对于我们的患者，深有其益。
真诚地祝愿第三届新药临床开发峰会再次成为一届以为中国及全球患者提供新药和新的医疗解决方案为宗旨的、面向未来的精彩研讨会。
祝大会圆满成功！
李元念博士
泰格医药高级副总裁
（中文致辞由胡小洁翻译，经李博士确认）
往届大会主席致辞